The discovery of the 'molecular switch' that causes inflammatory bowel disease (IBD) and Celiac disease, could lead to more effective new treatments for these life-changing auto-immune conditions, according to research from scientists at King's College London and University College London.
For the first time, researchers have a specific target for the treatment of these conditions by identifying an immune molecule called T-bet as the key control point that regulates this genetic risk in specific diseases. The discovery has been published in the journal PLoS Genetics.
T-bet plays an important role in coordinating the body's immune responses. In patients with IBD, T-bet behaves abnormally, causing the immune reaction which leads to the development of the condition.
A great deal of work has been done on the genetic predisposition to autoimmune disease over the past 10 years. However, it has been very difficult to develop effective treatments because a large number of genes each make a very small contribution to the development of these diseases.
Professor Graham Lord, co-senior author on the study and Director of the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, which supported this study, said: "Our research outlines a specific focus for the development of new treatments for these diseases which have such a profound effect on sufferers."
Co-senior author Dr Richard Jenner (UCL Cancer Institute) said: "Understanding how our DNA influences our risk of developing specific diseases is the key to developing precision therapies for the most severe illnesses. While there is still a great deal of work to be done before this work results in new treatments for patients, it is a significant breakthrough."